Phase Ib trial to evaluate the tolerability and pharmacokinetics of neoadjuvant WX 671 in patients with head and neck cancer.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Upamostat (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 24 Sep 2007 Results have been reported.
- 24 Sep 2007 Status changed from initiated to completed.